Clinical trials: Visceral Leishmaniasis
Leishmaniasis, Visceral
A Study Evaluating Sitamaquine Compared With Amphotericin B In The Treatment Of Visceral Leishmaniasis.
Sitamaquine is an 8-aminoquinoline which is being developed as an oral treatment for visceral leishmaniasis (VL). Pre-clinical and subsequent clinical investigations have demonstrated oral efficacy against Leishmania donovani.
- Trial name
- NCT00381394
- Testing
- sitamaquine
- Where
- 3 sites in India
- Volunteers
- 61 people
- Sponsor
- GlaxoSmithKline
Visceral Leishmaniasis
Efficacy and Safety Study of Drugs for Treatment of Visceral Leishmaniasis in Brazil
This study is aimed to compare the efficacy and safety of medications currently used in Brazil for treatment of visceral leishmaniasis.
- Trial name
- LVBrasil (NCT01310738)
- Testing
- Antimoniate of N-methylglucamine, amphotericin B deoxycholate, Liposomal amphotericin B
- Where
- 5 sites in Brazil
- Volunteers
- 378 people
- Sponsor
- University of Brasilia
Visceral Leishmaniasis, Malnutrition
Visceral Leishmaniasis and Malnutrition in Amhara Regional State, Ethiopia
The project Visceral Leishmaniasis and Malnutrition is a cohort study that aimed to assess the association between malnutrition and visceral leishmaniasis (VL).
- Trial name
- VL&MNEthio (NCT02148822)
- Volunteers
- 520 people
- Sponsor
- Instituto de Salud Carlos III
Visceral Leishmaniasis
A Study to Assess Immune Response Status in Patients Before and After Treatment for Visceral Leishmaniasis
ImmStat@Cure is a multicentre observational study designed to assess the immune status of patients before and after treatment for visceral leishmaniasis. Forty patients and 30 controls will be recruited per site.
- Trial name
- NCT04342715
- Testing
- Sodium stibogluconate / paramomycin
- Where
- Kenya
- Volunteers
- 216 people, healthy volunteers welcome
- Sponsor
- University of York
Visceral Leishmaniasis
Phase 1 LEISH-F3 + SLA-SE Vaccine Trial in Healthy Adult Volunteers
The purpose of this study is to compare the safety, tolerability, and immunogenicity in healthy adult subjects of an investigational vaccine being developed for the prevention of visceral leishmaniasis.
- Trial name
- NCT02071758
- Testing
- LEISH-F3 + SLA-SE, LEISH-F3 + GLA-SE
- Where
- United States
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- Access to Advanced Health Institute (AAHI)
Leishmaniasis, Leishmaniasis, Visceral
Clinical Investigation of Infections Due to Leishmanial Parasites
Mechanisms of host immune response to intracellular protozoa will be investigated in patients with naturally acquired infection employing a variety of in-vitro techniques.
- Trial name
- NCT00001169
- Where
- United States
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Visceral Leishmaniasis
Single Infusion of Liposomal Amphotericin B in Indian Visceral Leishmaniasis
The purpose of this trial is to evaluate the efficacy of single dose amphotericin B in the treatment of Visceral Leishmaniasis (VL) in India.
- Trial name
- NCT00628719
- Testing
- Liposomal Amphotericin B, amphotericin B deoxycholate
- Where
- India
- Volunteers
- 400 people
- Sponsor
- Banaras Hindu University
Visceral Leishmaniasis
Evaluation of Less Invasive Procedures for Visceral Leishmaniasis Treatment Efficacy Monitoring Test of Cure
Left untreated, visceral leishmaniasis (VL) is fatal. The highest burden of VL worldwide is in eastern Africa where field-adapted diagnostic and test-of-cure tools and treatment are lacking.
- Trial name
- VL-ToC (NCT05426577)
- Testing
- ELISA, LAMP, Cytokine Release Assay
- Where
- Ethiopia
- Volunteers
- 60 people
- Sponsor
- Foundation for Innovative New Diagnostics, Switzerland
Leishmaniasis, Cutaneous, Leishmaniasis
Ex Vivo Immunogenicity Screening of Vaccine Candidate Antigen Combinations in Ethiopian Patients With Leishmaniasis
This study assesses the immunoprevalence (presence of the induced T-cell response across different patients (and thus HLA types) of six prioritized IPX-derived Leishmania antigens, using Good Laboratory Practice-grade soluble…
- Conditions
- Leishmaniasis, Cutaneous, Leishmaniasis, Leishmaniasis, Visceral, Immunogenicity
- Trial name
- LEISHVAC (NCT07783243)
- Where
- 2 sites in Ethiopia
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Institute of Tropical Medicine, Belgium
Visceral Leishmaniasis
Amphotericin B to Treat Visceral Leishmaniasis in Brazilian Children
The purpose of this study is to determine if amphotericin B is effective against visceral leishmaniasis in Brazilian children. Amphotericin B will be compared to meglumine antimoniate which is the current approved drug used for…
- Trial name
- LVTO (NCT01032187)
- Testing
- Meglumine antimoniate, Amphotericin B-deoxycholate
- Where
- 2 sites in Brazil
- Volunteers
- 101 people
- Sponsor
- University of Brasilia
Visceral Leishmaniasis
Pharmacokinetics/Safety of Miltefosine Allometric Dose for the Treatment of Visceral Leishmaniasis in Children in Eastern Africa
This is a multicenter, non-comparative, open-label clinical trial to assess the Pharmacokinetics (PK) and safety of miltefosine using an allometric dose algorithm in the treatment of children with primary Visceral Leishmaniasis…
- Trial name
- NCT02431143
- Testing
- Miltefosine
- Where
- 2 sites in Kenya, Uganda
- Volunteers
- 30 people
- Sponsor
- Drugs for Neglected Diseases
Visceral Leishmaniasis, Chagas Disease
A First-in-human, Safety, Tolerability, and Pharmacokinetics Study of LXE408 in Healthy Subjects
The purpose of this first-in-human study is to generate the necessary safety, tolerability, and pharmacokinetics (PK) information that will support further clinical development of LXE408 for the treatment of patients with…
- Trial name
- NCT07809919
- Testing
- LXE408, Iohexol
- Where
- United States
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Visceral Leishmaniasis
Safety and Efficacy Study of Paromomycin to Treat Visceral Leishmaniasis
Symptomatic Visceral Leishmaniasis(VL)is fatal; Due to the increasing resistance to standard therapy with antimonials, there is a need for new safe, efficacious, low-cost therapies for the treatment of VL.
- Trial name
- NCT00216346
- Testing
- Paromomycin sulfate, Amphotericin B
- Where
- 4 sites in India
- Volunteers
- 667 people
- Sponsor
- PATH
Visceral Leishmaniasis
An Open Lable Randomised Study to Assess the Safety and Efficacy of Short Course Paromomycin in Visceral Leishmaniasis
It is a randomized, double-blind, multi-center, two-arm study intended to assess the safety and efficacy of three different doses/dose regimens of paromomycin administered intramuscularly as follows: 11 mg/kg/day for 14 days and…
- Trial name
- NCT00629031
- Testing
- Paromomycin
- Where
- India
- Volunteers
- 329 people
- Sponsor
- Banaras Hindu University
Visceral Leishmaniasis
Combination Chemotherapy for the Treatment of Indian Kala-Azar
The investigators are using a sequential design to combine miltefosine and AmBisome in different doses.
- Trial name
- NCT00370825
- Testing
- Combination therapy with AmBisome and miltefosine
- Where
- India
- Volunteers
- 200 people
- Sponsor
- Banaras Hindu University
Visceral Leishmaniasis
Single Dose Liposomal Amphotericin B for Visceral Leishmaniasis
The study is designed to determine the use of delivering point of care, rapid diagnosis with rK39 and treatment with AmBisome single dose of 10 mg/kg when administrated in the Primary Health Center (PHC) settings with regard to…
- Trial name
- NCT01566552
- Testing
- AMBISOME
- Where
- India
- Volunteers
- 1,300 people
- Sponsor
- Banaras Hindu University
Leishmaniasis, Effects of Immunotherapy
SCH708980 With and Without AmBisome for Visceral Leishmaniasis
Background: Visceral leishmaniasis (VL) is an infection caused by parasites carried by sand flies. The parasites cause fever, weight loss, and enlargement of the spleen and liver. They can also affect the blood and immune system.
- Trial name
- NCT01437020
- Testing
- SCH708980 Anti-IL-10 monoclonal, AmBisome
- Where
- 2 sites in India
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Visceral Leishmaniasis
Immunogenetics of Visceral Leishmaniasis
Visceral leishmaniasis is a potentially fatal disease caused in South America by the protozoan Leishmania chagasi. In neighborhoods with high exposure rates, the outcome of human infection with L.
- Trial name
- NCT00342823
- Where
- Brazil
- Volunteers
- 7,000 people, healthy volunteers welcome
- Sponsor
- National Human Genome Research Institute (NHGRI)
Primary Visceral Leishmaniasis
Clinical Trial to Assess the Safety and Efficacy of Sodium Stibogluconate (SSG) and AmBisome® Combination, Miltefosine and AmBisome® and Miltefosine Alone for the Treatment Visceral Leishmaniasis in Eastern Africa
This study is to assess if shorter combinations of SSG plus single dose AmBisome®, Miltefosine plus single dose AmBisome® and Miltefosine alone are effective in treating visceral leishmaniasis in Eastern Africa.
- Trial name
- NCT01067443
- Testing
- Liposomal amphotericin B (AmBisome®) and sodium stibogluconate, Liposomal amphotericin B + miltefosine, Miltefosine
- Where
- 3 sites in Kenya, Sudan
- Volunteers
- 151 people
- Sponsor
- Drugs for Neglected Diseases
Visceral Leishmaniasis
Open-Label, Sequential Step, Safety and Efficacy Study to Determine the Optimal Single Dose of Ambisome for Patients With VL
This is a phase II/III open, comparative dose trial to find the lowest single dose of AmBisome for the treatment of primary, symptomatic visceral leishmaniasis(VL), in HIV negative patients.
- Trial name
- NCT00832208
- Testing
- Liposomal amphotericin B (Ambisome)
- Where
- 3 sites in Ethiopia, Sudan
- Volunteers
- 124 people
- Sponsor
- Drugs for Neglected Diseases